Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adecoagro SA (AGRO) vs Eli Lilly And Co (LLY) Price & Performance

Adecoagro SA
Eli Lilly And Co

Price performance

Price movement over the last 24 hours

Key statistics

Adecoagro SA vs Eli Lilly And Co — how do they compare? Adecoagro SA trades at $10.12 (market cap $1.39B), while Eli Lilly And Co trades at $1,229.54 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 791.4× Adecoagro SA's market cap, and Adecoagro SA pays the higher dividend (3.08%). Which is the better fit depends on your goals.

AGROLLY
Market Cap
$1.39B$1.10T
Sector
TechnologyHealth
52-Week High
$15.25$1.24K
52-Week Low
$7.13$625.65
Enterprise Value
$3.42B$1.14T
Dividend Yield
3.08%0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adecoagro SA

AGRO trades at $9.48, down 1.66% today, with a bearish technical signal despite neutral oscillators. The company reported mixed quarterly results, missing Q1 2026 EPS estimates but showing strong adjusted EBITDA growth. Valuation metrics appear attractive with P/S of 0.71 and P/B of 0.78, though profitability remains weak with a 0.91% net margin. Recent news highlights innovation in agriculture operations and a declared $0.12 dividend for H1 2026.

The stock offers value appeal with below-market multiples and analyst consensus target of $12.75 implying 34% upside. However, inconsistent earnings performance and negative net income in 2025 pose execution risks. The bearish technical trend and competitive pressures in sustainable agriculture require careful monitoring for potential investors.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,235.56, up 2.07% today, with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. Revenue surged to $65.18B in 2025, with a net income margin of 34.99%, while analyst consensus is strongly positive with a $1,310 price target. Recent news highlights expansion in China for its breast cancer drug and bullish commentary from financial media on growth prospects.

The outlook remains favorable due to robust revenue growth and high profitability, though elevated valuation ratios and regulatory risks pose challenges. Upside is supported by analyst optimism and institutional interest, but investors should monitor competitive pressures and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adecoagro SA

Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.

Read more on AGRO

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY